Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 95

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 95
---
 licensors are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.

Our success also depends on our ability, and the
abilities of any of our respective current or future collaborators, to develop, manufacture, market and sell product candidates without
infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are
owned by third parties, exist in the fields in which we are developing products, some of which may be directed at claims that overlap
with the subject matter of our or our licensors’ intellectual property. Because patent applications can take many years to
issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates
or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we or our
licensors are not aware. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications in the U.S. and other jurisdictions are typically not published until 18 months after a first filing, or in some cases
not at all. Therefore, we cannot know with certainty whether we or such licensors were the first to make the inventions claimed in patents
or pending patent applications that we own or licensed, or that we and our licensors were the first to file for patent protection of such
inventions. In the event that a third party has also filed a U.S. patent application relating to our product candidates or a similar invention,
depending upon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by
the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that
our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent position.
As a result, the issuance, scope, validity, enforceability and commercial value of our or any of our licensors’ patent rights are
highly uncertain.

<div align='center'>49</div>

​

Table of Contents

There is a substantial amount of litigation involving
patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims
that we or any of our licensors, suppliers or collaborators infringe the third party’s intellectual property rights, we may have
to